Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,170.00
-45.00 (-1.40%)
Jun 27, 2025, 3:30 PM KST

Xcell Therapeutics Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
35,00344,384----
Upgrade
Enterprise Value
34,84338,298----
Upgrade
Last Close Price
3200.004065.00----
Upgrade
PS Ratio
20.0922.95----
Upgrade
PB Ratio
5.414.87----
Upgrade
P/TBV Ratio
6.045.17----
Upgrade
EV/Sales Ratio
20.0019.80----
Upgrade
Debt / Equity Ratio
0.860.632.730.690.383.54
Upgrade
Asset Turnover
0.140.140.090.050.100.05
Upgrade
Inventory Turnover
3.614.444.014.673.872.48
Upgrade
Quick Ratio
1.281.900.361.192.831.18
Upgrade
Current Ratio
1.562.140.521.392.931.29
Upgrade
Return on Equity (ROE)
-296.57%-165.90%-170.80%-67.53%-102.65%-
Upgrade
Return on Assets (ROA)
-50.72%-42.63%-43.01%-26.46%-18.88%-26.46%
Upgrade
Return on Capital (ROIC)
-63.73%-49.18%-48.12%-28.23%-24.84%-108.77%
Upgrade
Earnings Yield
-28.08%-21.50%----
Upgrade
FCF Yield
-27.25%-16.63%----
Upgrade
Buyback Yield / Dilution
-16.73%-13.14%-1.02%-5.71%-131.08%-107.45%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.